Ena Wang, M.D.
Director of Molecular Science, Infectious Diseases and Immunogenetics Section, Department of Transfusion Medicine, CC
Dr. Ena Wang obtained her Medical Doctor degree at Hebei Medical University, China in 1982 and a Master of Medicine in 1989 at Shanghai Medical University. Before coming to the United States, she was teacher associate for three years at the Department of Parasitology, Chengde Medical College and Chief Resident for two years at Shanghai Dermatology Institute, Shanghai China. She came to the United State in 1991 as Visiting Research Scientist at the Department of Microbiology and Immunology, AHSC, University of Arizona and continued her academic career as Assistant research scientist in the same department till 1997. In 1998, she was granted a Cancer Research Fellow position at the Surgery Branch, National Cancer Institute, National Institutes of Health. She was promoted to Staff Scientist in 2001 and appointed as Director of Molecular Sciences in 2007 at the Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center, National Institutes of Health.
During her career at NIH, Dr Wang was granted twice Investigator Travel Fellowship Award, she was recipient of an NIH Bench-to-Bedside Award in 2002; a recipient of Minority Award as a mentor and principle investigator in 2002, she was also recipient of the NCI Director’s 2006 Intramural Innovation Award as co-investigator in 2006 and recipient of the Clinic Center Director’s Award for scientific excellence in 2007.
She has contributed 17 book chapters and published more than 130 peer reviewed articles. The focus of her research is the identification of genetic traits in humans that could explain the relationship between pathogens and the host with particular interest in cancer and chronic infections. This analysis spans the study of germ line characteristics that could explain the influence of genetic background of the host in modulating disease evolution; the analysis also includes of the study of genetic alterations of cancer cells or pathogens at times relevant to disease outcome or response to therapy. Her work has focused extensively on the variation of cancer cells during its natural evolution or in response to therapy and developed technologies for the real-time analysis of evolving cancer phenotypes ex vivo in patients with melanoma and other cancers. Dr. Wang has also developed various platforms for the global analysis of individuals with cancer or chronic infections including gene expression, single nucleotide polymorphism and micro-RNA analysis using high-throughput solid platforms.
Last Updated July 2010